Hospital of Stomatology, Jilin University, Changchun, 130021, People's Republic of China.
Jilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, Changchun, 130021, People's Republic of China.
BMC Oral Health. 2024 Aug 29;24(1):1010. doi: 10.1186/s12903-024-04792-8.
Medication-related osteonecrosis of the Jaw (MRONJ) is a rare but severe side effect in patients treated with medications such as Bisphosphonates (BPs). Its pathophysiological mechanism needs to be more precise. Establishing preventive measures and treatment standards is necessary. This study aimed to develop a composite hydrogel scaffold constituted by methacrylated gelatin (GelMA), methacrylated heparin (HepMA) and PRF, and investigate its potential application value in the prevention of MRONJ.
GelMA, HepMA, and PRF were prepared using specific ratios for hydrogel scaffolds. Through mechanical properties and biocompatibility analysis, the release rate of growth factors and the ability to promote bone differentiation in vitro were evaluated. To explore the healing-enhancing effects of hydrogels in vivo, the composite hydrogel scaffold was implanted to the MRONJ rat model. Micro-computed tomography (Micro-CT) and histological examination were conducted to evaluate the bone morphology and tissue regeneration.
The Hep/GelMA-PRF hydrogel improved the degradation rate and swelling rate. It was also used to control the release rate of growth factors effectively. In vitro, the Hep/GelMA-PRF hydrogel was biocompatible and capable of reversing the inhibitory effect of zoledronic acid (ZOL) on the osteogenic differentiation of MC3T3-E1s. In vivo, the micro-CT analysis and histological evaluation demonstrated that the Hep/GelMA-PRF group exhibited the best tissue reconstruction. Moreover, compared to the ZOL group, the expression of osteogenesis proteins, including osteocalcin (OCN), type collagen I (Col I), and bone morphogenetic protein-2 (BMP-2) in the Hep/GelMA-PRF group were all significantly upregulated (P < 0.05).
The Hep/GelMA-PRF hydrogel scaffold could effectively control the release rate of growth factors, induce osteogenic differentiation, reduce inflammation, and keep a stable microenvironment for tissue repair. It has potential application value in the prevention of MRONJ.
药物相关性颌骨坏死(MRONJ)是接受双膦酸盐(BPs)等药物治疗的患者中一种罕见但严重的副作用。其病理生理机制需要更精确。建立预防措施和治疗标准是必要的。本研究旨在开发一种由甲基丙烯酰化明胶(GelMA)、甲基丙烯酰肝素(HepMA)和 PRF 组成的复合水凝胶支架,并研究其在预防 MRONJ 中的潜在应用价值。
使用特定比例的 GelMA、HepMA 和 PRF 制备 GelMA、HepMA 和 PRF。通过机械性能和生物相容性分析,评估生长因子的释放率和体外促进骨分化的能力。为了探讨水凝胶在体内的促愈合作用,将复合水凝胶支架植入 MRONJ 大鼠模型中。通过微计算机断层扫描(Micro-CT)和组织学检查评估骨形态和组织再生。
Hep/GelMA-PRF 水凝胶提高了降解率和溶胀率。它还能有效控制生长因子的释放速度。体外,Hep/GelMA-PRF 水凝胶具有生物相容性,并能逆转唑来膦酸(ZOL)对 MC3T3-E1s 成骨分化的抑制作用。体内,Micro-CT 分析和组织学评价表明,Hep/GelMA-PRF 组表现出最佳的组织重建。此外,与 ZOL 组相比,Hep/GelMA-PRF 组中成骨蛋白的表达,包括骨钙素(OCN)、I 型胶原(Col I)和骨形态发生蛋白-2(BMP-2)均显著上调(P<0.05)。
Hep/GelMA-PRF 水凝胶支架能有效控制生长因子的释放速度,诱导成骨分化,减少炎症,为组织修复保持稳定的微环境。它在预防 MRONJ 方面具有潜在的应用价值。